These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals. Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838 [TBL] [Abstract][Full Text] [Related]
45. Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs. Wei F; Pence L; Woodling K; Bagam P; Beger R; Gamboa da Costa G; Pang L Toxicol Sci; 2022 Jun; 188(1):48-61. PubMed ID: 35478258 [TBL] [Abstract][Full Text] [Related]
47. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes. Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424 [TBL] [Abstract][Full Text] [Related]
48. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue. Kawatou M; Masumoto H; Fukushima H; Morinaga G; Sakata R; Ashihara T; Yamashita JK Nat Commun; 2017 Oct; 8(1):1078. PubMed ID: 29057872 [TBL] [Abstract][Full Text] [Related]
49. Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters. Kilfoil P; Feng SL; Bassyouni A; Lee T; Leishman D; Li D; MacEwan DJ; Sharma P; Watt ED; Jenkinson S Eur J Pharmacol; 2021 Dec; 912():174584. PubMed ID: 34678241 [TBL] [Abstract][Full Text] [Related]
50. Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report. Mulder P; de Korte T; Dragicevic E; Kraushaar U; Printemps R; Vlaming MLH; Braam SR; Valentin JP J Pharmacol Toxicol Methods; 2018; 91():36-42. PubMed ID: 29355722 [TBL] [Abstract][Full Text] [Related]
51. Assessing proarrhythmic potential of environmental chemicals using a high throughput in vitro-in silico model with human induced pluripotent stem cell-derived cardiomyocytes. Lin HC; Rusyn I; Chiu WA ALTEX; 2024 Jan; 41(1):37-49. PubMed ID: 37921411 [TBL] [Abstract][Full Text] [Related]
52. A greedy classifier optimization strategy to assess ion channel blocking activity and pro-arrhythmia in hiPSC-cardiomyocytes. Raphel F; De Korte T; Lombardi D; Braam S; Gerbeau JF PLoS Comput Biol; 2020 Sep; 16(9):e1008203. PubMed ID: 32976482 [TBL] [Abstract][Full Text] [Related]
53. The Use of iPSC-Derived Cardiomyocytes and Optical Mapping for Erythromycin Arrhythmogenicity Testing. Podgurskaya AD; Tsvelaya VA; Slotvitsky MM; Dementyeva EV; Valetdinova KR; Agladze KI Cardiovasc Toxicol; 2019 Dec; 19(6):518-528. PubMed ID: 31165980 [TBL] [Abstract][Full Text] [Related]
54. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159 [TBL] [Abstract][Full Text] [Related]
55. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. Li M; Kanda Y; Ashihara T; Sasano T; Nakai Y; Kodama M; Hayashi E; Sekino Y; Furukawa T; Kurokawa J J Pharmacol Sci; 2017 Jun; 134(2):75-85. PubMed ID: 28615142 [TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment. Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283 [TBL] [Abstract][Full Text] [Related]
57. Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp. Verkerk AO; Veerman CC; Zegers JG; Mengarelli I; Bezzina CR; Wilders R Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28867785 [TBL] [Abstract][Full Text] [Related]
58. Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds. Green JR; Diaz GJ; Limberis JT; Houseman KA; Su Z; Martin RL; Cox BF; Kantor S; Gintant GA J Pharmacol Toxicol Methods; 2011; 64(1):68-73. PubMed ID: 21440075 [TBL] [Abstract][Full Text] [Related]